Terms: = Germ cell tumor AND HOXD13, SPD, 3239, P35453, HOX4I
42 results:
1. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
2. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
[TBL] [Abstract] [Full Text] [Related]
3. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed cell Death Protein PD-1.
Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
[TBL] [Abstract] [Full Text] [Related]
4. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract] [Full Text] [Related]
5. Differential diagnosis between pancreatic solid pseudopapillary tumors and pancreatic neuroendocrine tumors based on contrast enhanced ultrasound imaging features.
Zhang Q; Qiu YJ; Yang DH; Lu XY; Chen S; Dong Y; Wang WP
Clin Hemorheol Microcirc; 2023; 85(4):421-431. PubMed ID: 37718786
[TBL] [Abstract] [Full Text] [Related]
6. Predicting the survival of patients with pancreatic neuroendocrine neoplasms using deep learning: A study based on Surveillance, Epidemiology, and End Results database.
Jiang C; Wang K; Yan L; Yao H; Shi H; Lin R
Cancer Med; 2023 Jun; 12(11):12413-12424. PubMed ID: 37165971
[TBL] [Abstract] [Full Text] [Related]
7. Combined Radiomodifying Effect of Fucoidan from the Brown Alga
Malyarenko OS; Malyarenko TV; Usoltseva RV; Kicha AA; Ivanchina NV; Ermakova SP
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979354
[TBL] [Abstract] [Full Text] [Related]
8. Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
Liu X; Li Z; Sun J; Zhang Z; Li W
BMC Cancer; 2023 Mar; 23(1):259. PubMed ID: 36941554
[TBL] [Abstract] [Full Text] [Related]
9. Large, linear pigmentation anomaly: an unusual dyspigmentation case.
Vander Does A; Motosko C; Yosipovitch G
Dermatol Online J; 2022 Dec; 28(6):. PubMed ID: 36809100
[TBL] [Abstract] [Full Text] [Related]
10. Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.
Zhong J; Xiang D; Ma X
Biomed Res Int; 2022; 2022():2309339. PubMed ID: 35845958
[TBL] [Abstract] [Full Text] [Related]
11. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear spd-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract] [Full Text] [Related]
12. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract] [Full Text] [Related]
13. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
[TBL] [Abstract] [Full Text] [Related]
14. Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone tumors.
Kushlinskii NE; Alferov AA; Timofeev YS; Gershtein ES; Bulycheva IV; Bondarev AV; Shchupak MY; Sokolov NY; Polikarpova SB; Efimova MM; Dzampaev AA; Sushentsov EA; Aliev MD; Musaev ER
Bull Exp Biol Med; 2020 Nov; 170(1):64-68. PubMed ID: 33231796
[TBL] [Abstract] [Full Text] [Related]
15. The Change of Soluble Programmed cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract] [Full Text] [Related]
16. A novel miR-7156-3p-hoxd13 axis modulates glioma progression by regulating tumor cell stemness.
Zhang J; Deng M; Tong H; Xue W; Guo Y; Wang J; Chen L; Wang S
Int J Biol Sci; 2020; 16(16):3200-3209. PubMed ID: 33162825
[TBL] [Abstract] [Full Text] [Related]
17. Dynamic whole-body
Nishimura M; Tamaki N; Matsushima S; Kiba M; Kotani T; Bamba C; Nakamura Y; Yamada K
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2293-2300. PubMed ID: 32189027
[TBL] [Abstract] [Full Text] [Related]
18. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract] [Full Text] [Related]
19. CD24 and PRAME Are Novel Grading and Prognostic Indicators for Pineal Parenchymal tumors of Intermediate Differentiation.
Wu X; Wang W; Lai X; Zhou Y; Zhou X; Li J; Liang Y; Zhu X; Ren X; Ding Y; Liang L
Am J Surg Pathol; 2020 Jan; 44(1):11-20. PubMed ID: 31567202
[TBL] [Abstract] [Full Text] [Related]
20. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.
Pellegrini C; Botta F; Massi D; Martorelli C; Facchetti F; Gandini S; Maisonneuve P; Avril MF; Demenais F; Bressac-de Paillerets B; Hoiom V; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Marrett L; Zanetti R; Dwyer T; Thomas NE; Begg CB; Berwick M; Puig S; Potrony M; Nagore E; Ghiorzo P; Menin C; Manganoni AM; Rodolfo M; Brugnara S; Passoni E; Sekulovic LK; Baldini F; Guida G; Stratigos A; Ozdemir F; Ayala F; Fernandez-de-Misa R; Quaglino P; Ribas G; Romanini A; Migliano E; Stanganelli I; Kanetsky PA; Pizzichetta MA; García-Borrón JC; Nan H; Landi MT; Little J; Newton-Bishop J; Sera F; Fargnoli MC; Raimondi S; ; ;
Lancet Child Adolesc Health; 2019 May; 3(5):332-342. PubMed ID: 30872112
[TBL] [Abstract] [Full Text] [Related]
[Next]
